SERA Strangle Strategy
SERA (Sera Prognostics, Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NASDAQ.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
SERA (Sera Prognostics, Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $60.7M, a beta of 0.93 versus the broader market, a 52-week range of 1.37-4.09, average daily share volume of 57K, a public-listing history dating back to 2021, approximately 63 full-time employees. These structural characteristics shape how SERA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.93 places SERA roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on SERA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current SERA snapshot
As of May 15, 2026, spot at $1.76, ATM IV 234.40%, IV rank 50.44%, expected move 67.20%. The strangle on SERA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on SERA specifically: SERA IV at 234.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 67.20% (roughly $1.18 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SERA expiries trade a higher absolute premium for lower per-day decay. Position sizing on SERA should anchor to the underlying notional of $1.76 per share and to the trader's directional view on SERA stock.
SERA strangle setup
The SERA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SERA near $1.76, the first option leg uses a $1.85 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SERA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SERA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.85 | N/A |
| Buy 1 | Put | $1.67 | N/A |
SERA strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
SERA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on SERA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on SERA
Strangles on SERA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SERA chain.
SERA thesis for this strangle
The market-implied 1-standard-deviation range for SERA extends from approximately $0.58 on the downside to $2.94 on the upside. A SERA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SERA IV rank near 50.44% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on SERA should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SERA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SERA-specific events.
SERA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SERA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SERA alongside the broader basket even when SERA-specific fundamentals are unchanged. Always rebuild the position from current SERA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on SERA?
- A strangle on SERA is the strangle strategy applied to SERA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SERA stock trading near $1.76, the strikes shown on this page are snapped to the nearest listed SERA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SERA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SERA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 234.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SERA strangle?
- The breakeven for the SERA strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SERA market-implied 1-standard-deviation expected move is approximately 67.20%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on SERA?
- Strangles on SERA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SERA chain.
- How does current SERA implied volatility affect this strangle?
- SERA ATM IV is at 234.40% with IV rank near 50.44%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.